Premium
Rhinocerebral Mucormycosis in the Era of Lipid‐Based Amphotericin B: Case Report and Literature Review
Author(s) -
Mondy Kristin E.,
Haughey Bruce,
Custer Philip L.,
Wippold Franz J.,
Ritchie David J.,
Mundy Linda M.
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.7.519.33679
Subject(s) - amphotericin b , mucormycosis , nephrotoxicity , medicine , amphotericin b deoxycholate , antifungal , surgery , debridement (dental) , mycosis , dermatology , toxicity , caspofungin
Rhinocerebral mucormycosis (RCM) is an invasive fungal infection that necessitates, in most cases, aggressive surgical debridement and high cumulative, often nephrotoxic doses of amphotericin B. A 50‐year‐old woman with RCM was treated successfully with amphotericin B lipid complex as primary therapy. The patient previously had displayed progressive intracranial involvement and rising serum creatinine levels while receiving the conventional (nonlipid) form of amphotericin B. A literature review identified only a few cases where systemic antifungal therapy was administered, with minimal or no surgery. Our case further supports that amphotericin B lipid complex can be used as primary therapy in selected patients with RCM, without the need for surgical exenteration.